Prognostic utility of cardiac troponin in heart failure: A novel role for an established biomarker

Biomarkers in Medicine

Volumn 3, Issue 5, 2009, Pages 483-493

  Jackson, Colette E ^a   Dalzell, Jonathan R ^a   Gardner, Roy S ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

Author keywords

Acute decompensated heart failure; Chronic heart failure; Prognosis; Risk stratification; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DIGOXIN; TROPONIN; TROPONIN C; TROPONIN I; TROPONIN T; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC VALUE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; LUNG EDEMA; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; TACHYCARDIA;

EID: 70450265710     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.38     Document Type: Review

References (55)

1. Dickstein K, Cohen-Solal A, Filippatos G et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. J. Heart Fail. 10(10), 933-989 (2008).
2. 2+ saturated form. Nature 424(6944), 35-41 (2003).
3. Babuin L, Jaffe AS: Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 173(10), 1191-1202 (2005). ■ Comprehensive review of troponin as a biomarker in cardiac injury.
4. Thygesen K, Alpert JS, White HD et al.; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Circulation 116(22), 2634-2653 (2007).
5. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD; the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators: Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 354(9192), 1757-1762 (1999).
6. Morrow DA, Antman EM, Tanasijevic M et al.: Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J. Am. Coll. Cardiol. 36(6), 1812-1817 (2000).
7. Morrow DA, Cannon CP, Rifai N et al.; TACTICS-TIMI 18 Investigators: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 286(19), 2405-2412 (2001). (Pubitemid 33098158)
8. Antman EM, Tanasijevic MJ, Thompson B et al.: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N. Engl. J. Med. 335(18), 1342-1349 (1996). ■■ One of the earliest studies highlighting the relationship between troponin elevation and mortality risk.
9. Hamwi SM, Sharma AK, Weissman NJ et al: Troponin-I elevation in patients with increased left ventricular mass. Am. J. Cardiol. 92(1), 88-90 (2003) .
10. Lauer B, Niederau C, Kühl U et al.: Cardiac troponin T in patients with clinically suspected myocarditis. J. Am. Coll. Cardiol. 30(5), 1354-1359 (1997). (Pubitemid 27501457)
11. Brandt RR, Filzmaier K, Hanrath P: Circulating cardiac troponin I in acute pericarditis. Am. J. Cardiol. 87(11), 1326-1328 (2001) . (Pubitemid 32493886)
12. La Vecchia L, Ottani F, Favero L et al.: Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. Heart 90(6), 633-637 (2004). (Pubitemid 38668535)
13. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS: Cardiac troponins in renal insufficiency: review and clinical implications. J. Am. Coll. Cardiol. 40(12), 2065-2071 (2002). (Pubitemid 36005889)
14. ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK: Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin. Chem. 46(5), 650-657 (2000).
15. Cardinale D, Sandri MT, Colombo A et al.: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109(22), 2749-2754 (2004). (Pubitemid 38737923)
16. Bleier J, Vorderwinkler KP, Falkensammer J et al.: Different intracellular compartmentations of cardiac troponins and myosin heavy chains: a causal connection to their different early release after myocardial damage. Clin. Chem. 44(9), 1912-1918 (1998).
17. Antman EM: Decision making with cardiac troponin tests. N. Engl. J. Med. 346(26), 2079-2082 (2002). ■ Detailed review of the clinical utility of the troponin test.
18. Capasso JM, Malhotra A, Li P, Zhang X, Scheuer J, Anversa P: Chronic nonocclusive coronary artery constriction impairs ventricular function, myocardial structure, and cardiac contractile protein enzyme activity in rats. Circ. Res. 70(1), 148-162 (1992).
19. Clarke MS, Caldwell RW, Chiao H, Miyake K, McNeil PL: Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ. Res. 76(6), 927-934 (1995).
20. Kaye D, Pimental D, Prasad S et al.: Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J. Clin. Invest. 97(2), 281-291 (1996). (Pubitemid 126550054)
21. Page E, Upshaw-Earley J, Goings G: Permeability of rat atrial endocardium, epicardium, and myocardium to large molecules. Stretch-dependent effects. Circ. Res. 71(1), 159-173 (1992).
22. Hessel MH, Atsma DE, van der Valk EJ, Bax WH, Schalij MJ, van der Laarse A: Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch. 455(6), 979-986 (2008).
23. Ross RS, Borg TK: Integrins and the myocardium. Circ. Res. 88(11), 1112-1119 (2001).
24. Perna ER, Macín SM, Cimbaro Canella JP et al.: High levels of troponin T are associated with ventricular remodeling and adverse in-hospital outcome in heart failure. Med. Sci. Monit. 10(3), CR90-CR95 (2004).
25. Nishio Y, Sato Y, Taniguchi R et al.: Cardiac troponin T vs other biochemical markers in patients with congestive heart failure. Circ. J. 71(5), 631-635 (2007). (Pubitemid 46683349)
26. Missov E, Calzolari C, Pau B: Circulating cardiac troponin I in severe congestive heart failure. Circulation 96(9), 2953-2958 (1997). ■■ First study in heart failure to describe the potential clinical use of troponin in heart failure.
27. Horwich TB, Patel J, MacLellan WR, Fonarow GC: Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108, 833-838 (2003). (Pubitemid 37022125)
28. Hudson MP, O'Connor CM, Gattis WA et al.: Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective ana lysis. Am. Heart J. 147(3), 546-552 (2004).
29. Latini R, Masson S, Anand IS et al.; Val-HeFT investigators: Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116(11), 1242-1249 (2007). ■■ First study in heart failure demonstrating the prognostic significance of highly sensitive troponin.
30. Yin WH, Chen JW, Feng AN, Lin SJ, Young S: Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin. Cardiol. 30, 397-402 (2007).
31. Miller WL, Hartman KA, Burritt MF et al.: Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 116, 249-257 (2007).
32. Pascual-Figal DA, Manzano-Fernandez S, Pastor F et al.: Troponin-T monitoring in outpatients with nonischemic heart failure. Rev. Esp. Cardiol. 61(7), 678-686 (2008).
33. Sato Y, Yamada T, Taniguchi R et al.: Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 103(3), 369-374 (2001). (Pubitemid 32105975)
34. Eagle KA, Lim MJ, Dabbous OH et al.; GRACE Investigators: A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291(22), 2727-2733 (2004).
35. Morrow DA, Antman EM, Charlesworth A et al.: TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102(17), 2031-2037 (2000). (Pubitemid 30786479)
36. Levy WC, Mozaffarian D, Linker DT et al.: The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113(11), 1424-1433 (2006). (Pubitemid 43739439)
37. Pocock SJ, Wang D, Pfeffer MA et al.: Predictors of mortality and morbidity in patients with chronic heart failure. Eur. Heart J. 27(1), 65-75 (2006). (Pubitemid 41785934)
38. Wedel H, McMurray JJ, Lindberg M et al.; on behalf of the CORONA study group: Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal proB-type natriuretic peptide. Eur. J. Heart Fail. 11(3), 281-291 (2009).
39. Felker GM, Leimberger JD, Califf RM et al.: Risk stratification after hospitalization for decompensated heart failure. J. Card. Fail. 10(6), 460-466 (2004).
40. Fonarow GC, Adams KF Jr, Abraham WT et al.; ADHERE Scientific Advisory Committee, Study Group and Investigators: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree ana lysis. JAMA 293(5), 572-580 (2005).
41. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM: Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95(12), 2660-2667 (1997).
42. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV: Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290(19), 2581-2587 (2003). (Pubitemid 37443288)
43. Vazquez R, Bayes-Genis A, Cygankiewicz I et al.; on behalf of MUSIC investigators: The MUSIC risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur. Heart J. 30(9), 1088-1096 (2009). ■ Only prognostic risk score in heart failure that includes troponin.
44. Ishii J, Nomura M, Nakamura Y et al.: Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am. J. Cardiol. 89(6), 691-695 (2002). (Pubitemid 34230565)
45. Gheorghiade M, Gattis Stough W, Adams KF Jr, Jaffe AS, Hasselblad V, O'Connor CM: The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am. J. Cardiol. 96(6A), 18G-25G (2005). (Pubitemid 41338070)
46. You JJ, Austin PC, Alter DA, Ko DT, Tu JV: Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am. Heart J. 153(4), 462-470 (2007).
47. Shah MR, Hasselblad V, Tasissa G et al.: Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). Am. J. Cardiol. 100(9), 1427-1433 (2007).
48. Metra M, Nodari S, Parrinello G et al.: The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur. J. Heart Fail. 9(8), 776-786 (2007). (Pubitemid 47212835)
49. Sakhuja R, Green S, Oestreicher EM et al.: Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure. Clin. Chem. 53(3), 412-420 (2007).
50. Peacock WF 4th, De Marco T, Fonarow GC et al.; ADHERE investigators: Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med. 358(20), 2117-2126 (2008).
51. Fonarow GC, Peacock WF, Horwich TB et al.; ADHERE Scientific Advisory Committee and investigators: Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am. J. Cardiol. 101(2), 231-237 (2008).
52. Johnson W, Omland T, Hall C et al.: Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J. Am. Coll. Cardiol. 39(10), 1623-1629 (2002). (Pubitemid 34494285)
53. Fitzgerald RL, Cremo R, Gardetto N et al.: Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am. Heart J. 150(3), 471-477 (2005).
54. Del Carlo CH, Pereira-Barretto AC, Cassaro-Strunz C, Latorre Mdo R, Ramires JA: Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. J. Card. Fail. 10(1), 43-48 (2004). (Pubitemid 38880891)
55. Kuwabara Y, Sato Y, Miyamoto T et al.: Persistently increased serum concentrations of cardiac troponin in patients with acutely decompensated heart failure are predictive of adverse outcomes. Circ. J. 71(7), 1047-1051 (2007). (Pubitemid 46998018)